Ductal carcinoma in situ of the breast (Report of 78 cases)

doi:10.3969/j.issn.1674-490X.2015.01.006

Abstract

Abstract: Objective To explore the clinical and pathological characteristics of ductal carcinoma in situ (DCIS) with tumor size examination. Methods We retrospectively analyzed 78 DCIS cases in Affiliated Hospital of Hebei University from Feb. 2011 to Sep. 2013. A comparative analysis was conducted with the cut-off points of 1.0 cm and 3.0 cm tumor size. Results When tumor size≤1.0 cm and tumor size between 1.0-3.0 cm, the clinical characteristics had no significant difference, when tumor size>3.0 cm, the characteristics were significantly different from the above two (P<0.05) shown as micro infiltration, high multifocal proportion, and high sentinel lymph node positive rate. The variance analysis of pathological indicators of DCIS and IDC showed that the positive expression of ER, PR, Ki67 was relatively low, while the positive expression of HER-2 was relatively high (P<0.05), this difference was significant. When tumor size >3 cm, all the indicators had no significant difference. Conclusion When tumor size>3.0 cm, the DCIS is more aggressive and its biology characteristics are similarly to IDC. The IDC treatment is recommended.

Key words: DCIS, breast cancer, diagnosis

CLC Number:

R737.9

LIN Xiaomeng, SHI Jianwei, WANG Jian, LI Zhong. Ductal carcinoma in situ of the breast (Report of 78 cases)[J]. Medical Reserch and Education, 2015, 32(1): 26-30.

References

[1] ZUJEWSKI J A, HARLAN L C, MORRELL D M, et al. Ductal carcinoma in situ: trends in treatment over time in the US[J]. Breast Cancer Res Treat, 2011, 127(1): 251-257.
[2] LAGIOS M D, MARGOLIN F R, WESTDAHL P R, et al. Mammagraphically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence[J]. Cancer, 1989, 63(1): 618-627.
[3] SAKR R, ANTOINE M, BARRANGER E, et al. Value of sentinel lymphnode biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma[J]. Breast J, 2008, 14(3): 325-328.
[4] 李世超, 齐晓伟. 美国临床肿瘤学会和美国病理学家学会乳腺癌雌激素/孕激素受体免疫组化检测指南[J]. 中华乳腺病杂志: 电子版, 2011, 5(3): 385-387.
[5] GOLDHIRSEH A, WOOD W C, COATES A S, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.
[6] 李树玲. 乳腺肿瘤学[M]. 北京: 科学技术文献出版社, 2000: 561.
[7] MAFFUZ A, BARROSE-BRAVO S, NAJERA I, et al. Tumor size as predictor of micminvasion, invasion, and axillary metastasis in ductal carcinoma in situ[J]. Exp Clin Cancer Res, 2006, 25(2): 223-227.
[8] SAKR R, BARRANGER E, ANTOINE M, et al. Ductal carcinoma in situ: value of sentinel lymph node biopsy[J]. Surg Oncol, 2006, 94(5): 426-430.
[9] YERUSHALMI R, KENNECKE H, WOODS R, et al. Does multicentric multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence[J]. Breast cancer Res Treat, 2009, 117(2): 365-370.
[10] COOMBS M, BOYAGES J. Multffocal and multieentrle breast cancer: does each focus matter[J]. J Clin Oncol, 2005, 23(30): 7497-7502.
[11] CHEN A M, MERLE-BEMSTAM F, HUNT K K, et al. Breast conservation after nooacljuvant chemotherapy [J]. Cancer, 2005, 103(4): 689-695.
[12] 李美蓉, 范松青, 张利群, 等. 乳腺癌激素受体和癌基因的表达及临床意义[J]. 中国医师杂志, 2006, 8(1): 34-37.
[13] 杨超, 刘志英, 肖刚, 等. 乳腺导管内癌与浸润性导管癌激素受体表达比较[J]. 山东医药, 2008, 48(25): 114.
[14] HAN K, NOFECH-MOZES S, NAROD S, et al. Expression of HER-2neu in ductal carcinoma in situ is associated with local recurrence[J]. Clin Oncol: R Coll Radi0l, 2012, 24(3): 183-189.
[15] 钱秀珍, 钱永坤. 乳腺导管原位癌与浸润性导管癌激素受体及 HER-2 表达的比较[J/CD]. 中华乳腺病杂志, 2013, 7(2): 97-101.
[16] 新杰, 周文斌, 周冬仙, 等. C-erbB-2, ER 及 PR 表达在乳腺导管内癌与浸润性导管癌的对照研究[J]. 中国普通外科杂志, 2008, 17(12): 1226-1228.
[17] SANTISTEBAN M, REYNOLDS C, BARR FRITCHER E G, et al. Ki67: a timevarying biomarker of risk of breast cancer in atypical hyperplasia[J]. Breast Callcer Res Treat, 2010, 121(2): 431-437.

Related Articles 15

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(5): 29-37.
[2]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 14-21.
[3]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(2): 39-43.
[4]	ZHAN Xiaofei, CUI Zhenyu, ZHAO Chunli. Advances on artificial intelligence in the diagnosis and treatment of urinary calculi [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(4): 30-38.
[5]	WANG Jing, HAN Li, ZHANG Zeming. Advances on chronic obstructive pulmonary disease associated pulmonary hypertension [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 21-28.
[6]	WEI Yali,SUN Chengcheng,WANG Xiaochun. Advances on vasculogenic mimicry in breast cancer [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(2): 16-23.
[7]	. [J]. Journal of Hebei Medical College for Continuing Education, 2021, 38(5): 7-14.
[8]	. [J]. Journal of Hebei Medical College for Continuing Education, 2021, 38(1): 64-69.
[9]	. [J]. Journal of Hebei Medical College for Continuing Education, 2020, 37(6): 23-28.
[10]	. [J]. Journal of Hebei Medical College for Continuing Education, 2020, 37(4): 43-48.
[11]	. [J]. Journal of Hebei Medical College for Continuing Education, 2020, 37(3): 18-27.
[12]	. [J]. Medical Reserch and Education, 2020, 37(2): 1-12.
[13]	. [J]. Medical Reserch and Education, 2020, 37(1): 36-40.
[14]	. [J]. Medical Reserch and Education, 2020, 37(1): 14-20.
[15]	. [J]. Medical Reserch and Education, 2019, 36(6): 44-47.